Well thought out response. Not to be dismissive, but we have seen far too many small studies report an overestimated treatment effect to take any too seriously (except perhaps early CAR-T in b-cell lymphoma). We are ready and willing to publicly acknowledge EPA is a wonderfully effective “drug” at reducing risk of ASCVD, but must insist it comes from a robustly sized, adequate and well-controlled trial. We have yet to see any of those Japanese studies fit that category.
News 
Market Data 
Discover 
AI
